efore and soon after IPW weightingPre-IPW Weighting (n = 340) Outcome at 30d All VTE recurrence PE/DVT recurrence All bleeding Key bleedingaPost-IPW Weighting (n = 340) P-value 1.00 n/a 0.20 0.47 Continue three 1 41 7 Hold 4 0 32 five ATEa -1.5 +0.eight +9.9 +2.2 P-value 0.61 n/a 0.08 0.Continue three 1 42 7Hold two 0 35 4Average treatment impact (ATE) may be the anticipated benefit or adverse outcome if all of the individuals within the HOLD group were instead continuedon anticoagulation. Abbreviations: IPW, inverse-probability weighting; ATE = average remedy effect; VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep venous thrombosis Conclusions: In sufferers taking anticoagulant medication for prior VTE, temporarily withholding anticoagulant therapy might minimize bleeding without having significantly escalating risk of CD40 Antagonist supplier recurrent VTE inside the very first 30 days following HCT. PB1245|Effectiveness and Safety of DOACs for the Prevention of Recurrent VTE: A Prospective Cohort Study A. Vinci1; M.C. Vedovati1; M.G. De Natale1; L. BRD4 Modulator supplier Pierpaoli2; F. Di Filippo2; G. Agnelli1; C. BecattiniUniversity of Perugia, Perugia, Italy; 2S. Maria delle Croci Hospital,Ravenna, Italy Background: Within the direct oral anticoagulants (DOACs) era, extended anticoagulation right after 62 months of treatment is definitely an eye-catching method in individuals with venous thromboembolism (VTE). Real-life data around the clinical benefit of DOAC more than time is lacking. Aims: The aim of this study is to assess the effectiveness and safety of DOACs in patients with acute VTE treated for variable periods. Strategies: Data on patients with an objective diagnosis of acute VTE treated with DOACs have been integrated in prospective cohort study. Study outcomes were recurrent VTE and key bleeding (ISTH definition). Final results: Overall, 934 individuals have been included (imply age 67.06.0, male gender 51.4 ). Three-hundred and forty-six patients had a deep vein thrombosis (37.0 ), 98 (ten.five ) had isolated pulmonary embolism and 490 (52.five ) had both. One-hundred and sixty-nine patients (18.1 ) had an active cancer, 59 (6.three ) a history of cancer and 365 patients (39.1 ) an unprovoked VTE. In the course of DOAC remedy (mean 21.6 months), 7 recurrent VTEs and 25 important bleedings occurred. In 546 and in 98 individuals, DOAC was continued with complete and lowered doses, respectively. In 290 individuals (43.eight unprovoked, 13.8 active cancer, 42.4 related with non-cancer risk aspect), anticoagulants were withdrawn (typical remedy duration eight.eight months) and 22 recurrent VTEs occurred over a followup off-treatment period of 31.9 months. In these individuals, 2 episodes of important bleeding had been observed. General, 201 sufferers died; fatal PE occurred in four and fatal bleeding in 1 patient. Time course for recurrent VTE in line with 2019 ESC threat for recurrence is reported in the Figure. Conclusions: In this cohort study, DOACs showed a fantastic danger to benefit profile inside the extended phase following an acute VTE event. FIGURE 1 Cumulative incidence of recurrent VTE914 of|ABSTRACTPB1246|Antithrombotic Management of Sufferers with Deep Vein Thrombosis and Venous Stents: An International Registry A. Cervi1; D. Applegate2; S.M. Stevens2,3; S.C. Woller2,three; L. Baumann Kreuziger4; K. Puchhalapalli4; T.-F. Wang5; R. Lecumberri6; S. Schulman7,8; G. Foster9,10; J. Douketis1PB1247|Security Profile of Rivaroxaban in First-time Users Treated for Deep Vein Thrombosis and Pulmonary Embolism devoid of a Current History of Cancer A. Ruigomez1; T. Schink two; A. Voss2; R.MC Herings3; E. Smits3; K. S